Literature DB >> 11358329

Co-expression of two LTB4 receptors in human mononuclear cells.

T Yokomizo1, T Izumi, T Shimizu.   

Abstract

Leukotriene B4 (LTB4) is one of the most potent chemoattractants and activators of leukocytes, and is involved in inflammatory diseases. Two G-protein-coupled-receptors for LTB4, BLT1 and BLT2, have been isolated, and shown to be a high- and low-affinity receptor, respectively. The tissue distributions of these receptors are different, and distinct roles of each receptor remain elusive. We compared the expression of these two receptors using semi-quantitative PCR analyses, and show that these two receptors are expressed in various subsets of human lymphocytes in different quantities. BLT1 expression is highest in CD14+ monocytes, while BLT2 expression is high in CD8+ cytotoxic T-, CD4+ helper T-, and CD19+ B-cells. Moreover, BLT2 expression in these lymphocytes decreased upon activation of the cells. We also established CHO cells stably expressing both receptors, and found that these cells could migrate toward LTB4 with a broad range of LTB4. These findings suggest novel roles of LTB4 in immune system, and the biological significance of high- and low- affinity LTB4 receptors in chemotaxis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358329     DOI: 10.1016/s0024-3205(01)01007-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Leukotriene Inhibitors in Sinusitis.

Authors:  John W Steinke; Joshua L Kennedy
Journal:  Curr Infect Dis Rep       Date:  2012-01-29       Impact factor: 3.725

2.  The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans.

Authors:  Sabina A Islam; Seddon Y Thomas; Christoph Hess; Benjamin D Medoff; Terry K Means; Christian Brander; Craig M Lilly; Andrew M Tager; Andrew D Luster
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

3.  Mass spectrometric analysis of leukotriene A4 and other chemically reactive metabolites of arachidonic acid.

Authors:  Jennifer S Dickinson; Robert C Murphy
Journal:  J Am Soc Mass Spectrom       Date:  2002-10       Impact factor: 3.109

Review 4.  Leukotriene synthesis inhibitors versus antagonists: the pros and cons.

Authors:  John W Steinke; Jeffrey A Culp
Journal:  Curr Allergy Asthma Rep       Date:  2007-05       Impact factor: 4.806

5.  Human articular chondrocytes express functional leukotriene B4 receptors.

Authors:  Ann Kristin Hansen; Jill-Tove Indrevik; Yngve Figenschau; Inigo Martinez-Zubiaurre; Baldur Sveinbjörnsson
Journal:  J Anat       Date:  2015-02-09       Impact factor: 2.610

6.  Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis.

Authors:  Rainer Spanbroek; Rolf Grabner; Katharina Lotzer; Markus Hildner; Anja Urbach; Katharina Ruhling; Michael P W Moos; Brigitte Kaiser; Tina U Cohnert; Thorsten Wahlers; Arthur Zieske; Gabriele Plenz; Horst Robenek; Peter Salbach; Hartmut Kuhn; Olof Radmark; Bengt Samuelsson; Andreas J R Habenicht
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

7.  Differential Contribution of BLT1 and BLT2 to Leukotriene B4-Induced Human NK Cell Cytotoxicity and Migration.

Authors:  Meng Wang; Nermine Mostafa El-Maghraby; Sylvie Turcotte; Marek Rola-Pleszczynski; Jana Stankova
Journal:  Mediators Inflamm       Date:  2015-12-01       Impact factor: 4.711

8.  Proinflammatory and immunoregulatory roles of eicosanoids in T cells.

Authors:  Anna Mari Lone; Kjetil Taskén
Journal:  Front Immunol       Date:  2013-06-04       Impact factor: 7.561

Review 9.  Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review.

Authors:  Amjad M Qandil
Journal:  Int J Mol Sci       Date:  2012-12-17       Impact factor: 5.923

10.  CD36 Shunts Eicosanoid Metabolism to Repress CD14 Licensed Interleukin-1β Release and Inflammation.

Authors:  Karina F Zoccal; Luiz G Gardinassi; Carlos A Sorgi; Alyne F G Meirelles; Karla C F Bordon; Isaias Glezer; Palmira Cupo; Alessandra K Matsuno; Valdes R Bollela; Eliane C Arantes; Francisco S Guimarães; Lúcia Helena Faccioli
Journal:  Front Immunol       Date:  2018-04-27       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.